- Trials with a EudraCT protocol (1,948)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
1,948 result(s) found for: Adenocarcinoma.
Displaying page 17 of 98.
EudraCT Number: 2006-001518-34 | Sponsor Protocol Number: ML20296 | Start Date*: 2006-07-17 |
Sponsor Name:Roche Farma, S.A. | ||
Full Title: Estudio fase II abierto, no aleatorizado, de erlotinib en combinación con gemcitabina en pacientes con adenocarcinoma de páncreas avanzado irresecable o metastásico: relación entre rash cutáneo y ... | ||
Medical condition: Adenocarcinoma de páncreas avanzado irresecable o metastásico [Advanced unresectable or metastatic adenocarcinoma of the pancreas]. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-000050-22 | Sponsor Protocol Number: SEGCG18-01 | Start Date*: 2018-04-24 | |||||||||||
Sponsor Name:Skåne University Hospital, Department of Oncology | |||||||||||||
Full Title: Irinotecan-based triplet (FOLFOXIRI) as perioperative treatment in resectable gastric and gastroesophageal junction adenocarcinoma. | |||||||||||||
Medical condition: Resectabel gastric and gastroesophageal junction adenocarcinoma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002909-25 | Sponsor Protocol Number: 74310 | Start Date*: 2020-10-21 |
Sponsor Name:Amsterdam University Medical Centers | ||
Full Title: Blood-borne assessment of stromal activation in esophageal adenocarcinoma to guide tocilizumab therapy: a randomized phase II proof-of-concept study | ||
Medical condition: oesophageal adenocarcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003080-26 | Sponsor Protocol Number: CASSANDRA | Start Date*: 2020-10-14 | |||||||||||
Sponsor Name:FONDAZIONE GISCAD (GRUPPO ITALIANO PER LO STUDIO DEI CARCINOMI DELL'APPARATO DIGERENTE) | |||||||||||||
Full Title: A randomized phase II trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma (PDAC). | |||||||||||||
Medical condition: Patients with pancreatic ductal adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004792-30 | Sponsor Protocol Number: HE316 | Start Date*: 2018-10-03 | |||||||||||
Sponsor Name:Hellenic Cooperative Oncology Group (HeCOG) | |||||||||||||
Full Title: Phase Ib-II study of Ramucirumab combined with standard Nab-paclitaxel and Gemcitabine as first-line treatment in patients with advanced pancreatic adenocarcinoma | |||||||||||||
Medical condition: Advanced pancreatic adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005696-24 | Sponsor Protocol Number: MS200095-0022 | Start Date*: 2016-07-04 |
Sponsor Name:Merck KGaA | ||
Full Title: A Phase II, single-arm trial to investigate tepotinib in advanced (locally advanced or metastatic) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (V... | ||
Medical condition: Advanced (stage IIIB/IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Ongoing) DE (Ongoing) ES (Ongoing) FR (Ongoing) AT (Completed) NL (Ongoing) IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002331-25 | Sponsor Protocol Number: BP27836 | Start Date*: 2011-12-07 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: An Open-Label, Randomized, Multicenter Phase IIa Study Evaluating Pertuzumab in Combination with Trastuzumab and Chemotherapy in Patients with HER2-Positive Advanced Gastric Cancer | |||||||||||||
Medical condition: HER2-positive adenocarcinoma of the stomach or gastroesophageal junction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) BE (Completed) CZ (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001495-38 | Sponsor Protocol Number: XYN-602 | Start Date*: 2019-02-05 | ||||||||||||||||
Sponsor Name:Xynomic Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Randomized, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma | ||||||||||||||||||
Medical condition: Locally Advanced or Metastatic Renal Cell Carcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005648-25 | Sponsor Protocol Number: PHRC/07-03/RENNES | Start Date*: 2008-01-31 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:C.H.U. de RENNES | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Carcinome rénal à cellules claires (CRCC) traité par molécules antiangiogéniques en situation adjuvante: valeur pronostique et thérapeutique des altérations du gène VHL et de l’expression plasmatiq... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Carcinome rénal à cellules claires (CRCC) traité par molécules antiangiogéniques en situation adjuvante | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002773-38 | Sponsor Protocol Number: AIO-KRK-0214 | Start Date*: 2016-12-20 | |||||||||||||||||||||
Sponsor Name:AIO-Studien-gGmbH | |||||||||||||||||||||||
Full Title: mFOLFOX6 vs. mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial | |||||||||||||||||||||||
Medical condition: Patients with locally advanced rectal or rectosigmoid cancer staged cT3 CRM-negative with MRI | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004572-34 | Sponsor Protocol Number: MM-141-07-02-02 | Start Date*: 2016-09-16 | |||||||||||
Sponsor Name:Merrimack Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 plus Nab-paclitaxel and Gemcitabine versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer | |||||||||||||
Medical condition: Patients with metastatic adenocarcinoma of the pancreas who have not received prior therapy for their metastatic disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001066-42 | Sponsor Protocol Number: GETNE-T1812 | Start Date*: 2020-02-20 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Spanish Group of Neuroendocrine Tumors (GETNE) | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma - The DUTHY trial | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Advanced, radioiodine-refractory differentiated thyroid carcinoma, including papillary, follicular, Hürtle Cell and poorly-differentiated thyroid carcinoma (DTC). Advanced medullary thyroid carcino... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002269-47 | Sponsor Protocol Number: STH18441 | Start Date*: 2015-12-02 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | ||||||||||||||||||||||||||||||||||||||
Full Title: Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy. | ||||||||||||||||||||||||||||||||||||||
Medical condition: Iodine-refractory thyroid cancer of papillary, follicular, Hürthle cell or poorly differentiated carcinoma | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000742-21 | Sponsor Protocol Number: 2017/2527 | Start Date*: 2017-07-31 | |||||||||||||||||||||
Sponsor Name:Gustave Roussy | |||||||||||||||||||||||
Full Title: Efficacy of a selective MEK (trametinib) and BRAFV600E (dabrafenib) inhibitors associated with radioactive iodine (RAI) for the treatment of refractory metastatic differentiated thyroid cancer with... | |||||||||||||||||||||||
Medical condition: Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients with RAS or BRAF mutation | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002419-48 | Sponsor Protocol Number: GETNE-T2216 | Start Date*: 2023-03-27 | |||||||||||||||||||||
Sponsor Name:Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE) | |||||||||||||||||||||||
Full Title: Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. | |||||||||||||||||||||||
Medical condition: Patients with radioiodine-refractory differentiated thyroid cancer (DTC). | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001902-14 | Sponsor Protocol Number: D5760C00001 | Start Date*: 2017-11-06 | ||||||||||||||||||||||||||
Sponsor Name:MedImmune LLC, a wholly owned subsidiary of AstraZeneca PLC | ||||||||||||||||||||||||||||
Full Title: A Phase 1/2 Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI4276 in Subjects with Select H... | ||||||||||||||||||||||||||||
Medical condition: HER2 expressing Advanced Solid Tumors | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002873-47 | Sponsor Protocol Number: SOGUG2011-03 | Start Date*: 2011-11-25 | |||||||||||
Sponsor Name:Grupo Español de Oncología Genitourinaria (SOGUG) | |||||||||||||
Full Title: PHASE II CLINICAL TRIAL OF DOVITINIB (TKI-258) IN FIRST-LINE METASTATIC OR LOCALLY ADVANCED NON-RESECTABLE ADRENOCORTICAL CARCINOMA | |||||||||||||
Medical condition: Carcinoma adrenocortical metastásico o localmente avanzado no resecable, confirmado histológicamente. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005748-12 | Sponsor Protocol Number: 2012.761 | Start Date*: 2013-04-26 | |||||||||||
Sponsor Name:Hospices Civils de Lyon | |||||||||||||
Full Title: D2 Resection and HIPEC (Hyperthermic intraperitoneal chemoperfusion) in locally advanced gastric carcinoma. A national randomized and multicentric phase III study | |||||||||||||
Medical condition: Gastric adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004699-21 | Sponsor Protocol Number: CP-MGAH22-06 | Start Date*: 2020-10-12 | |||||||||||||||||||||
Sponsor Name:MacroGenics, Inc. | |||||||||||||||||||||||
Full Title: A Phase 2/3 Trial to Evaluate Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients with Metastatic or Locally Advanced, Treatment-naïve, HER2-Positiv... | |||||||||||||||||||||||
Medical condition: Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) PL (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-014563-39 | Sponsor Protocol Number: 1200.42 | Start Date*: 2010-03-02 |
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | ||
Full Title: Phase III randomized trial of BIBW 2992 plus weekly paclitaxel versus Investigator’s choice of chemotherapy following BIBW 2992 monotherapy in non-small cell lung cancer patients failing previous... | ||
Medical condition: Patients with NSCLC stage IIIb and IV after failure of treatment with erlotinib or gefitinib | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) FR (Completed) ES (Completed) BE (Completed) FI (Completed) GB (Completed) HU (Completed) IT (Completed) AT (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.